• 1. Isoflavonoids of the Leguminosae
  Nigel C. Veitch Nat. Prod. Rep. 2007 24 417
• 2. Isoflavonoids of the Leguminosae
  Nigel C. Veitch Nat. Prod. Rep. 2013 30 988
• 3. Historical textile dyeing with Genista tinctoria L.: a comprehensive study by UPLC-MS/MS analysis
  Lore G. Troalen,Ashley S. Phillips,David A. Peggie,Perdita E. Barran,Alison N. Hulme Anal. Methods 2014 6 8915
• 4. Isoflavonoids and related compounds
  Gerard M. Boland,Dervilla M. X. Donnelly Nat. Prod. Rep. 1998 15 241
• 5. Lesser in vitro anaerobic cecal isoflavone disappearance was associated with greater apparent absorption of daidzein and genistein in Golden Syrian hamsters
  Mathieu Renouf,Suzanne Hendrich Food Funct. 2011 2 273

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Isoflavonoids Isoflavones
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Isoflavonoids Isoflav-2-enes Isoflavones
• Isoflavones
• Flavonoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Glycitein (CAS No. 40957-83-3): A Comprehensive Overview of Its Biochemical Significance and Recent Research Developments

Glycitein, a naturally occurring flavonoid derivative, is widely recognized for its profound biological activities and therapeutic potential. With the chemical identifier CAS No. 40957-83-3, this compound has garnered significant attention in the field of chemobiology and pharmacology. Flavonoids, a class of polyphenolic compounds, are renowned for their antioxidant, anti-inflammatory, and anticancer properties, and Glycitein stands out as one of the most promising among them.

The molecular structure of Glycitein consists of a flavonoid backbone with modifications that enhance its bioavailability and efficacy. Specifically, it is an isomer of genistein, differing by the presence of a hydroxyl group at the 6-position of the B-ring. This structural distinction contributes to its unique pharmacokinetic profile and interaction with various biological targets.

In recent years, extensive research has been conducted to elucidate the mechanisms through which Glycitein exerts its beneficial effects. Studies have demonstrated that Glycitein exhibits potent antioxidant activity by scavenging reactive oxygen species (ROS) and enhancing the activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase. This property is particularly relevant in the context of oxidative stress-related diseases, including neurodegenerative disorders like Alzheimer's disease and Parkinson's disease.

Furthermore, Glycitein has been shown to possess significant anti-inflammatory properties. It modulates key pro-inflammatory signaling pathways, such as nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), thereby reducing the production of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These findings make Glycitein a promising candidate for the development of therapeutic strategies against chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease.

One of the most compelling areas of research involving Glycitein is its role in cancer prevention and treatment. Preclinical studies have indicated that Glycitein can inhibit the proliferation of various cancer cell lines by inducing apoptosis, inhibiting cell cycle progression, and suppressing angiogenesis. Notably, it has been found to exhibit selective toxicity toward cancer cells while sparing normal cells, suggesting its potential as a chemopreventive agent. The molecular mechanisms underlying these effects include the modulation of signaling pathways such as Wnt/β-catenin, PI3K/Akt/mTOR, and p53-dependent apoptosis.

Recent advances in metabolomics have provided deeper insights into the metabolic fate of Glycitein in vivo. Studies using high-resolution mass spectrometry have identified several metabolites derived from Glycitein, including glucuronide conjugates and methylated derivatives. These metabolites contribute to the prolonged half-life and extended bioactivity of Glycitein in vivo. Additionally, these findings have implications for drug formulation and delivery systems aimed at optimizing the bioavailability and therapeutic efficacy of Glycitein-based drugs.

The potential applications of Glycitein extend beyond its well-documented health benefits. Emerging research suggests that it may play a role in cardiovascular protection by improving endothelial function and reducing oxidative stress in blood vessels. Furthermore, preliminary studies have explored its potential in managing metabolic disorders such as diabetes by enhancing insulin sensitivity and reducing hyperglycemia.

The synthesis and isolation of pure Glycitein remain challenging due to its limited natural abundance in plant sources. However, advancements in biotechnological methods have enabled the production of high-purity Glycitein through microbial fermentation using engineered strains or plant cell culture systems. These innovations hold promise for scaling up production while maintaining cost-effectiveness for pharmaceutical applications.

In conclusion, Glycitein (CAS No. 40957-83-3) is a multifaceted flavonoid with a broad spectrum of biological activities that make it an attractive candidate for therapeutic intervention in various diseases. The combination of its potent antioxidant, anti-inflammatory, anticancer properties with recent discoveries in its metabolic pathways underscores its significance in modern medicine. As research continues to uncover new aspects of its pharmacological profile, Glycitein is poised to become an integral component of future therapeutic strategies aimed at improving human health.

• 574-12-9(Isoflavone)
• 1157-39-7(4',7-Dimethoxyisoflavone)
• 446-72-0(Genistein)
• 485-72-3(Formononetin)
• 491-80-5(Biochanin A)
• 17817-31-1(Desmethylglycitein)
• 552-59-0(Prunetin)
• 798-61-8(Trimethoxyisoflavone)
• 485-63-2(3',4',7-Trihydroxyisoflavone)
• 486-66-8(Daidzein)